Phospho-FGFR4 (Tyr642) Antibody

What is the molecular significance of FGFR4 phosphorylation at tyrosine 642?

Tyrosine 642 is a key autophosphorylation site within the kinase domain of FGFR4. Phosphorylation at this residue occurs following ligand binding (typically fibroblast growth factors) to the extracellular domain of FGFR4, which promotes receptor dimerization. This autophosphorylation is essential for full activation of FGFR4's intrinsic tyrosine kinase activity and serves as a critical step in initiating downstream signaling cascades, including MAPK and PI3K/AKT pathways . The phosphorylation state at Tyr642 can be used as a direct readout of FGFR4 activation status in experimental systems, making antibodies against this modification valuable tools for studying receptor activity .

What research applications are Phospho-FGFR4 (Tyr642) antibodies validated for?

Based on the available data, Phospho-FGFR4 (Tyr642) antibodies have been validated for multiple applications:

Researchers should note that optimal dilutions should be determined empirically for each specific experimental system . The most consistently validated application across different manufacturers is Western blotting, with Jurkat cells frequently cited as a positive control .

How should I design experiments to verify antibody specificity for phosphorylated FGFR4?

To verify the specificity of Phospho-FGFR4 (Tyr642) antibodies, consider implementing the following experimental approaches:

• Phosphatase treatment control: Treat half of your sample with lambda phosphatase to remove phosphorylation. A specific phospho-antibody should show significantly reduced or absent signal in the dephosphorylated sample.

• Stimulation/inhibition experiments: Compare samples from cells treated with FGF ligands (particularly FGF1 or FGF19) to stimulate phosphorylation versus cells treated with FGFR-specific tyrosine kinase inhibitors.

• siRNA knockdown validation: Use FGFR4-specific siRNAs to reduce FGFR4 expression, as demonstrated in studies examining FGFR4 function in ovarian cancer cells . The antibody signal should decrease proportionally to the knockdown efficiency.

• Immunoprecipitation followed by Western blot: Immunoprecipitate FGFR4 using a total FGFR4 antibody, then probe with the phospho-specific antibody, or vice versa .

• Peptide competition assay: Pre-incubate the antibody with the phosphorylated peptide immunogen to block specific binding sites before application to your samples .

What cell lines and experimental conditions are optimal for detecting phosphorylated FGFR4?

Several cell lines have been identified as suitable models for studying phosphorylated FGFR4:

• Jurkat (JK) cells: Consistently recommended as a positive control for Western blot applications across multiple antibody manufacturers .

• Ovarian cancer cell lines: OVCA432 and other ovarian cancer lines have been used successfully in FGFR4 phosphorylation studies .

• Gastric and pancreatic cancer cell lines: These exhibit high FGFR4 expression as FGFR4 is naturally expressed in gastrointestinal epithelial cells and pancreas .

• Colorectal cancer cell lines: HT29, SW480, and HCT116 have been used in studies examining FGFR4 function and polymorphic variants .

For optimal detection of phosphorylated FGFR4, stimulate cells with 10 ng/mL FGF1 for approximately 6 hours before lysis . Phosphatase inhibitors must be included in lysis buffers to preserve phosphorylation status during sample preparation .

How can I quantitatively assess FGFR4 phosphorylation in response to therapeutic interventions?

For quantitative assessment of FGFR4 phosphorylation in therapeutic contexts, consider these methodological approaches:

• HTRF Assay: Homogeneous Time-Resolved Fluorescence assays for Phospho-FGFR4 (Tyr642) provide a plate-based, no-wash format for quantitative assessment of phosphorylation levels. This method uses two labeled antibodies: one specific to the phosphorylated motif and another that recognizes the protein independent of its phosphorylation state .

• Western Blot with Normalization: Quantify phospho-FGFR4 signal intensity relative to total FGFR4 expression using digital image analysis. This approach controls for changes in total protein expression that might confound phosphorylation data.

• Reporter Systems: Cells stably transduced with reporter response elements can be used to monitor downstream effects of FGFR4 phosphorylation. After FGFR4 manipulation and stimulation with FGF1, cell lysates can be analyzed according to the manufacturer's instructions using a plate reader .

• Cell Survival Assays: The effect of FGFR4 phosphorylation status on cell survival can be quantitatively assessed using water-soluble tetrazolium salt (WST-1) reagent following treatment with various compounds .

What is known about the differential regulation of FGFR4 Tyr642 phosphorylation in cancer versus normal tissues?

FGFR4 expression and phosphorylation status have been implicated in cancer progression, with important differences between normal and malignant tissues:

• Tissue expression pattern: FGFR4 is normally expressed in gastrointestinal epithelial cells, pancreas, and at lower levels in other tissues . Phosphorylation levels are typically tightly regulated in normal tissues.

• Cancer implications: Elevated FGFR4 expression and phosphorylation have been observed in gastric, pancreatic, and ovarian cancers . In high-grade serous ovarian cancer, FGFR4 protein expression has prognostic value, and functional studies have demonstrated that FGFR4 silencing affects cancer cell growth, survival, invasiveness, and apoptosis .

• Genetic variants impact: Polymorphic alleles of FGFR4 (particularly the Arg388 variant) demonstrate differential effects on phosphorylation and downstream signaling, which influence cancer progression. These variants show altered colony formation capacity, migration potential, and anchorage-independent growth in colorectal cancer models .

• Potential for targeted therapy: The differential phosphorylation of FGFR4 in cancer makes it a potential therapeutic target. Studies have evaluated both FGFR4-specific siRNAs and FGFR4 trap proteins encapsulated in nanoliposomes as potential treatment strategies .

How do experimental artifacts and technical considerations impact phospho-FGFR4 detection?

Researchers should be aware of several technical considerations that can affect phospho-FGFR4 detection:

• Sample preparation timing: Phosphorylation is a transient modification easily lost during sample processing. Immediate addition of phosphatase inhibitors to lysis buffers is critical .

• Antibody cross-reactivity: Due to high sequence conservation among FGFR family members, antibodies may cross-react with phosphorylated sites on other FGFRs. Validation using FGFR4 knockdown cells is recommended .

• Multiple bands in Western blot: Various post-translational modifications, particularly glycosylation, can result in mobility shifts during electrophoresis. Full maturation of glycan chains in the Golgi is essential for high-affinity interaction with FGF19, and differential glycosylation can result in multiple bands .

• Receptor internalization: Following activation, FGFR4 undergoes internalization, which can affect detection depending on subcellular fractionation methods. Membrane versus total cell lysate preparations may yield different results .

• Freeze-thaw cycles: Multiple freeze-thaw cycles can significantly reduce antibody performance. Storage recommendations specify keeping the antibody at -20°C and avoiding repeated freeze-thaw cycles .

How does phosphorylated FGFR4 function in different model systems and tissue contexts?

FGFR4 phosphorylation has distinct functions across different model systems:

• Cancer models: Phosphorylated FGFR4 promotes proliferation, invasion, and survival in various cancer models. In ovarian cancer, FGFR4 signaling activates both MAPK and PI3K/AKT pathways downstream of phosphorylation .

• Liver metabolism: Phosphorylated FGFR4 plays a critical role in bile acid metabolism. FGFR4 is required for normal down-regulation of CYP7A1 (the rate-limiting enzyme in bile acid synthesis) in response to FGF19 .

• Skeletal muscle development: FGFR4 phosphorylation contributes to myogenic differentiation, suggesting tissue-specific functions beyond cancer progression .

• Lung development: FGFR4 has been implicated in postnatal lung development, with phosphorylation status potentially regulating this process .

When designing experiments across these different model systems, researchers should consider the specific cellular contexts and potential co-factors that might influence FGFR4 phosphorylation and downstream effects.

What are the best strategies for studying FGFR4 phosphorylation in complex tissue samples versus cell lines?

Analyzing FGFR4 phosphorylation in complex tissues presents different challenges than in cell line models:

• Immunohistochemistry optimization: For tissue sections, optimization of antigen retrieval methods is critical. Phospho-epitopes can be particularly sensitive to fixation methods. Both paraffin (IHC-p) and frozen sections (IHC-f) protocols may be used, but require specific optimization .

• Proximity to phosphatases: In complex tissues, endogenous phosphatases may rapidly dephosphorylate FGFR4 during sample collection. Immediate snap-freezing of tissue samples and inclusion of phosphatase inhibitors during homogenization is essential.

• Contextual analysis: In tissues, FGFR4 expression is heterogeneous across cell types. Consider using dual immunofluorescence with cell-type-specific markers to identify which cells exhibit phosphorylated FGFR4.

• Tissue microarrays: For comparing phospho-FGFR4 across multiple tissue samples, tissue microarrays can provide standardized conditions for antibody staining and comparative analysis.

• Laser-capture microdissection: For highly specific analysis of particular cell populations within complex tissues, this technique can isolate cells of interest before phospho-FGFR4 analysis.

What are common troubleshooting approaches when phospho-FGFR4 detection fails?

When encountering difficulties in detecting phosphorylated FGFR4, consider these troubleshooting steps:

• Verification of phosphorylation stimulus: Ensure that the experimental conditions actually induced FGFR4 phosphorylation. Consider time-course experiments with FGF1 or FGF19 stimulation (10 ng/mL) for different durations .

• Sample preparation assessment: Check that phosphatase inhibitors were properly included in all buffers and that samples were processed quickly to preserve phosphorylation .

• Antibody validation: Verify antibody performance using a positive control sample, such as lysate from Jurkat cells .

• Dilution optimization: The recommended dilution ranges (1:500-1:2000 for Western blot) are guidelines. Empirical optimization with a dilution series may be necessary for your specific experimental system .

• Detection method sensitivity: If signal is weak, consider using enhanced chemiluminescence (ECL) systems with higher sensitivity or longer exposure times .

• Pre-enrichment strategy: For low-abundance phospho-FGFR4, consider immunoprecipitation with total FGFR4 antibody followed by Western blot with phospho-specific antibody .

How can I determine if changes in FGFR4 phosphorylation are biologically significant versus technical variation?

Distinguishing biological significance from technical variation requires rigorous experimental design:

• Multiple biological replicates: At minimum, three independent biological replicates should be performed to establish statistical significance of observed changes.

• Quantitative analysis: Use digital image analysis software to quantify band intensities in Western blots, normalizing phospho-FGFR4 signal to total FGFR4 and a loading control.

• Functional correlation: Correlate changes in phosphorylation with functional outcomes, such as downstream pathway activation (MAPK, PI3K/AKT), cell proliferation, or invasion assays .

• Dose-response relationships: Establish dose-response curves for stimulators or inhibitors to demonstrate a graded relationship between treatment and phosphorylation.

• Kinetic analysis: Examine the temporal dynamics of phosphorylation changes to distinguish transient fluctuations from sustained biological effects.

• Positive and negative controls: Include both positive controls (known FGFR4 activators) and negative controls (FGFR inhibitors or FGFR4 knockdown) in each experiment to establish the dynamic range of phosphorylation detection .